Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Company Description (as filed with the SEC)
We are a commercial biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan diseases. Our products, RAVICTI® (glycerol phenylbutyrate) Oral liquid, BUPHENYL® and AMMONAPS® (sodium phenylbutyrate) Tablets and Powder, are designed to lower ammonia in the blood. Ammonia is produced in the intestine after a person eats protein and is normally detoxified in the liver by conversion to urea. Elevated levels of ammonia are potentially toxic and can lead to severe medical complications which may include death. We have developed RAVICTI, which we launched during the first quarter of 2013, to treat most urea cycle disorders ("UCD") including 7 of the 8 and the most prevalent UCD subtypes, and are developing glycerol phenylbutyrate ("GPB"), the active pharmaceutical ingredient in RAVICTI, to treat hepatic encephalopathy ("HE"). UCD and HE are diseases in which blood ammonia is elevated. ... More ...
Where does HPTX fit in the risk graph?
|Annual EPS Est:||$1.34|
|Quarterly EPS Est:||0.17|